NCT00071071View on ClinicalTrials.gov

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

May 5, 2004

Study Completion Date

May 5, 2004

Conditions
Cutaneous T-Cell Lymphoma
Interventions
DRUG

HuMax-CD4

HuMax-CD4 280 mg was administered as a subcutaneous (SC) infusion once daily (OD) up to 18 weeks.

DRUG

HuMax-CD4

HuMax-CD4 560 mg was administered as a SC infusion OD up to 18 weeks.

Trial Locations (2)

94305-5152

Stanford University Med. Ctr., Dept. of Dermatology, Stanford

77030-4009

University of Texas, M.D. Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Genmab
All Listed Sponsors
lead

Genmab

INDUSTRY

NCT00071071 - Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. | Biotech Hunter | Biotech Hunter